Abstract
Purpose: Two years of adjuvant abemaciclib with endocrine therapy was approved by NICE [1] in July 2022 for hormone receptor-positive (HR+) HER2-negative (HER2–) node-positive early breast cancer (EBC) at high-risk of recurrence. There is concern around additional oncology service provision needs of this cohort who would previously have been discharged to surveillance. We have therefore reviewed our service to estimate the impact of this additional treatment on projected service provision needs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
